Neoplasm

In the study involving 1725 B-ALL patients, 264 were identified by microarray-based algorithm to have a Ph-like expression signature. Next generation sequencing (RNAseq, WGS, and/or WES) performed on … (full text at CIViC)

PMID 25207766 · Roberts et al., 2014 · Open in CIViC

Patients with metastatic colorectal cancer with STRN-ALK fusion, sporadic microsatellite instability high (MSI-H) and KRAS R164Q received ALK inhibitor ceritinib. After pts received ceritinib perinumb… (full text at CIViC)

PMID 26933125 · Yakirevich et al., 2016 · Open in CIViC

One Patient with soft tissue sarcoma and a STRN-NTRK2 fusion had a partial Response with larotrectinib. Treatment was done within a multicentre, open-label, phase 1/2 study and enrolled infants, child… (full text at CIViC)

PMID 29606586 · Laetsch et al., 2018 · Open in CIViC

In a sonic hedgehog driven medulloblastoma patient derived xenograft harbouring a SUFU deletion, SMO inhibition with LDE225 (Sonidegib) did not affect cell proliferation.

PMID 24651015 · Kool et al., 2014 · Open in CIViC

68 Caucasian men with metastatic castration resistant prostate cancer underwent treatment with abiraterone acetate. 832 single nucleotide polymorphisms (SNPs, Illumina OmniExpress) of 61 candidate gen… (full text at CIViC)

PMID 27150425 · Agarwal et al., 2016 · Open in CIViC

Overexpression and high p-SYK/SYK ratio were associated with resistance to paclitaxel. Inhibition of SYK with R406 resensitized cell lines to paclitaxel.

PMID 26096845 · Yu et al., 2015 · Open in CIViC

Trop2 (TACSTD2) levels were evaluated from 234 patients who underwent radical prostatectomy. These levels were found to be significantly correlated with recurrence (P=0.01), with 58 patients displayin… (full text at CIViC)

PMID 31932422 · Hsu et al., 2020 · Open in CIViC

TROP2 T256R mutation alters the plasma membrane localization and cell-surface binding of hRS7, the humanized antibody incorporated into Sacituzumab Govitecan (SG). The TROP2 T256R encoded protein was … (full text at CIViC)

PMID 34404686 · Coates et al., 2021 · Open in CIViC

A case report of a 74 year old female who was diagnosed with MPAL, B/myeloid with bone marrow blasts were positive for myeloperoxidase, CD19, and CD22. Chromosome analysis showed 46,XX,+1,der(1;18)(q1… (full text at CIViC)

PMID 27607436 · Yamamoto et al., 2016 · Open in CIViC

Preclinical study in melanoma cell lines. TBK1 depletion (siRNA) inhibited migration and invasion, whereas its constitutive overexpression led to an increase in invasion. In MEK-resistant NRAS mutant … (full text at CIViC)

PMID 24962318 · Vu et al., 2014 · Open in CIViC

This study included 1389 cases of high-risk pediatric B-ALL, of which 284 were identified by TaqMan Low Density Array to have a BCR-ABL1-like (Ph-like) gene expression signature. RT-PCR or RNAseq perf… (full text at CIViC)

PMID 28408464 · Reshmi et al., 2017 · Open in CIViC

The authors applied exome sequencing to14 relapsed/refractory (R/R) DLBCL patients and implicated these genes

PMID 26608593 · Mareschal et al., 2016 · Open in CIViC

All chordomas including 14 conventional chordomas and 7 poorly differentiated chordomas exhibited nuclear expression of brachyury (TBX2) by IHC whereas only 2 of 30 atypical teratoid/rhabdoid tumors w… (full text at CIViC)

PMID 27067307 · Hasselblatt et al., 2016 · Open in CIViC

shRNA knockdown of TBXT in the JHC7 chordoma cell line with TBXT amplification resulted in differentiation and growth arrest.

PMID 21699479 · Hsu et al., 2011 · Open in CIViC

All chordomas including 14 conventional chordomas and 7 poorly differentiated chordomas exhibited nuclear expression of brachyury (TBXT) by IHC whereas only 2 of 30 atypical teratoid/rhabdoid tumors w… (full text at CIViC)

PMID 27067307 · Hasselblatt et al., 2016 · Open in CIViC

This pediatric patients harboured a chordoma with high TBXT expression when compared with TCGA and POG570 data, and a high CD8+ infiltration score. The patient was treated with nivolumab, and experien… (full text at CIViC)

PMID 34931022 · Williamson et al., 2021 · Open in CIViC

Knockdown of TBXT in the U-CH1 chordoma cell line with polysomy of chromosome 6 decreased proliferation and induced a senescence-like phenotype.

PMID 21171078 · Presneau et al., 2011 · Open in CIViC

Knockdown of TBXT in the U-CH1 chordoma cell line with polysomy of chromosome 6 decreased proliferation and induced a senescence-like phenotype.

PMID 21171078 · Presneau et al., 2011 · Open in CIViC

To understand the role of TCF19 expression in NRAS-mutant melanoma, an analysis of a TCGA cutaneous melanoma data set showed that patient survival was inversely correlated with levels of BRD4 and TCF1… (full text at CIViC)

PMID 29650805 · Echevarría-Vargas et al., 2018 · Open in CIViC

In this 2018 study the authors investigated B cell precursor acute lymphoblastic leukemia (BCP ALL) RNA-seq data from 1,223 cases enrolled in various clinical trials across multiple centers. The patie… (full text at CIViC)

PMID 30487223 · Li et al., 2018 · Open in CIViC

In this 2023 study the authors investigated the occurrence and spectrum of TCF3 gene rearrangements in 203 patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL), aged 0-18. The study u… (full text at CIViC)

PMID 37058324 · Zerkalenkova et al., 2023 · Open in CIViC

First described in Schmitz but has been observed in multiple other BL studies

PMID 22885699 · Schmitz et al., 2012 · Open in CIViC

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours listed TCF3::PBX1 rearrangement in the essential diagnostic criteria for “B-lymphoblastic leukaemia/lymphoma … (full text at CIViC)

PMID 35732829 · Alaggio et al., 2022 · Open in CIViC

This is a large cohort study led by St Jude Children's Research Hospital with extensive genome-wide molecular profiles of 2754 children with acute lymphoblastic leukemia(ALL). Consistent with the prof… (full text at CIViC)

PMID 36050548 · Brady et al., 2022 · Open in CIViC

In an in vitro kinase study, the recombinant TEK R849W mutant kinase demonstrated resistance to bosutinib treatment at concentrations of 1μM and 10μM (activity %: 77 and 35) when compared to wild type… (full text at CIViC)

PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC

In B-lymphoblastic leukemia/lymphoma (B-ALL), the presence of this fusion is associated with so-called BCR/ABL1 like (Ph-like) subtype of the disease. The TERF2-JAK2 fusionis rare. This study was cond… (full text at CIViC)

PMID 27894077 · Boer et al., 2017 · Open in CIViC

In the study involving 1725 B-ALL patients, 264 were identified by microarray-based algorithm to have a Ph-like expression signature. Next generation sequencing (RNAseq, WGS, and/or WES) performed on … (full text at CIViC)

PMID 25207766 · Roberts et al., 2014 · Open in CIViC

In patients with acral lentiginous melanoma, those with amplification of TERT had shorter overall survival.

PMID 25219713 · Diaz et al., 2014 · Open in CIViC

In patients with papillary thyroid cancer harboring both BRAF V600E and the TERT promotor mutation C228T, recurrence-free survival is worse than in patients harboring one of these mutations or no muta… (full text at CIViC)

PMID 25024077 · Xing et al., 2014 · Open in CIViC

In 308 thyroid fine-needle aspiration biopsies, 0 of the 179 benign tumors displayed either the C228T or the C250T TERT promoter mutation; however, 9 of the 129 differentiated thyroid cancers had eith… (full text at CIViC)

PMID 25121551 · Liu et al., 2014 · Open in CIViC

TERT promoter mutations are activating and commonly found at two hotspots within the TERT promoter region which occur 124 and 146 base pairs (hg19) upstream of the translation start site. These hotspo… (full text at CIViC)

PMID 23955565 · Nonoguchi et al., 2013 · Open in CIViC

A total of 96 histopathologically confirmed RCC cases and corresponding normal tissues were subjected to hTERT gene expression using real-time PCR. Two RCC cell lines viz. ACHN and A498 were treated w… (full text at CIViC)

PMID 28215740 · Pal et al., 2017 · Open in CIViC

In 187 patients with glioblastoma, those with TERT promoter mutations had worse cummulative survival than wild-type patients. The most common mutation was C228T (73% of mutants) followed by C250T (27%… (full text at CIViC)

PMID 23955565 · Nonoguchi et al., 2013 · Open in CIViC

Patients with mutations at TERT promoter region of -124 and -146 of ATG showed poor survival in the absence but not in the presence of the variant allele of a common polymorphism with ID of rs2853669 … (full text at CIViC)

PMID 24101484 · Rachakonda et al., 2013 · Open in CIViC

In a retrospective study on TCGA data, the presence of non-synonymous mutations in TET1 is enriched in patients responding to immune checkpoint inhibitor treatment (n=519, P = 0.003). In an ICI-treate… (full text at CIViC)

PMID 31623662 · Wu et al., 2019 · Open in CIViC

In a cohort of 783 young adult patients with acute myeloid leukemia, those with TET2 mutations did not have significantly different rates of complete recovery, refractory disease, or hypoplastic death… (full text at CIViC)

PMID 22430270 · Gaidzik et al., 2012 · Open in CIViC